ORGANOGENESIS HOLDINGS INC (ORGO)
US68621F1021 - Common Stock
Spotlight: Healthcare and Tech VTAK, ORGO, CDIO, LAZR, VLCN
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
ORGO Stock Earnings: Organogenesis Hldgs Beats EPS, Beats Revenue for Q1 2024
ORGO stock results show that Organogenesis Hldgs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
ORGO Stock Earnings: Organogenesis Hldgs Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Organogenesis Hldgs (NASDAQ:ORGO) just reported results for the first quarter o...
Organogenesis (ORGO) Q1 2024 Earnings Call Transcript
ORGO earnings call for the period ending March 31, 2024.
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Let's take a look at the stocks that are in motion in today's session.
What's going on in today's session
What's going on in today's session
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Thursday's session: gap up and gap down stocks
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Commit To Purchase Organogenesis Holdings At $2.50, Earn 33.2% Annualized Using Options
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.
Why Organogenesis Holding Stock Plummeted by 18% Today
A double miss put the wound care specialist's shares on the sick list.
Organogenesis (ORGO) Q4 2023 Earnings Call Transcript
ORGO earnings call for the period ending December 31, 2023.
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Cantor starts Organogenesis at overweight, cites differentiated portfolio (NASDAQ:ORGO)
Cantor Fitzgerald has started coverage of Organogenesis (ORGO) with an overweight rating, citing attractive valuation and the company’s highly differentiated technology portfolio.
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Commit To Purchase Organogenesis Holdings At $2.50, Earn 7.6% Annualized Using Options
Organogenesis (ORGO) Q3 2023 Earnings Call Transcript
ORGO earnings call for the period ending September 30, 2023.
Organogenesis Holdings GAAP EPS of $0.02, revenue of $108.5M (NASDAQ:ORGO)
Organogenesis Holdings press release (NASDAQ:ORGO): Q3 GAAP EPS of $0.02.Revenue of $108.5M (-7.2% Y/Y).Sees 2023 Net revenue between $433 million and $446...
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
CANTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Commit To Purchase Organogenesis Holdings At $2.50, Earn 38% Annualized Using Options
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
CANTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
Organogenesis stock rises on Medicare update (NASDAQ:ORGO)
Organogenesis Holdings (ORGO) welcomes three Medicare Administrative Contractors' decision to pull final local coverage determinations (LCDs). Read more here.
Why Shares of Organogenesis Holdings Are Up Thursday
The company said it learned that its products will again be covered by three Medicare Administrative Contractors.